Suscribirse

Do NSAIDs Affect Longitudinal Changes in Knee Cartilage Volume and Knee Cartilage Defects in Older Adults? - 12/08/11

Doi : 10.1016/j.amjmed.2009.03.022 
Changhai Ding, MD a, b, , Flavia Cicuttini, PhD b, Graeme Jones, MD a
a Menzies Research Institute, University of Tasmania, Hobart, Australia 
b Department of Epidemiology and Preventive Medicine, Monash University Medical School, Melbourne, Australia 

Requests for reprints should be addressed to Changhai Ding, MD, Menzies Research Institute, Private Bag 23, Hobart, Tasmania 7000, Australia

Abstract

Background

The effects of nonsteroidal anti-inflammatory drugs (NSAIDs) on knee osteoarthritis progression are unclear. The aim of this longitudinal study was to determine the associations between use of NSAIDs and changes in knee cartilage volume and knee cartilage defects over 2.9 years in older adults.

Methods

T1-weighted fat-suppressed magnetic resonance imaging on the right knee was performed in a total of 395 randomly selected subjects (mean age 62 years, range 51-80 years, and 50% female) to assess knee cartilage volume at tibial sites and knee cartilage defects (0-4 scale) at baseline and 2.9 years later. Medication use in the last month was recorded by questionnaire.

Results

Compared with nonusers of NSAIDs (n=334), users of cyclooxygenase (COX)-2 inhibitors (n=40) had decreased knee cartilage defect development in the medial tibiofemoral compartment (odds ratio [OR] 0.4, 95% confidence interval [CI], 0.2-0.99), whereas users of conventional NSAIDs (n=21) had increased knee cartilage defect development in both medial (OR 3.1, 95% CI, 1.0-9.1) and lateral (OR 2.6, 95% CI, 1.0-6.7) tibiofemoral compartments. Comparing users of COX-2 inhibitors with users of conventional NSAIDs, the latter had higher knee cartilage volume loss (−5.3% vs −3.1% at medial tibia and −3.6% vs −1.1% at lateral tibia; all P <.05). All associations were adjusted for potential confounders including knee pain and radiographic osteoarthritis.

Conclusions

This study suggests that nonselective NSAIDs may have deleterious effects, while selective COX-2 inhibitors might have beneficial effects on knee cartilage. Randomized controlled trials examining knee structure to confirm this finding are warranted.

El texto completo de este artículo está disponible en PDF.

Keywords : Cartilage loss, Knee, Magnetic resonance imaging, Nonsteroidal anti-inflammatory drugs, Osteoarthritis


Esquema


 Funding: National Health and Medical Research Council of Australia; Arthritis Foundation of Australia; Tasmanian Community Fund; University of Tasmania Grant-Institutional Research Scheme.
 Conflict of Interest: Dr. Jones has worked as a consultant, speaker, and clinical trialist with Pfizer, MSD, Roche, and Novartis, all of which manufacture NSAIDs. However, none of these companies had any input into the writing of this article. Other authors have nothing to declare.
 Authorship: All authors had access to the data in the study. Study design: Ding, Cicuttini, Jones. Acquisition of data: Ding, Jones. Analysis and interpretation of data: Ding, Cicuttini, Jones. Manuscript preparation: Ding, Cicuttini, Jones. Statistical analysis: Ding, Jones.


Crown Copyright © 2009  Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 122 - N° 9

P. 836-842 - septembre 2009 Regresar al número
Artículo precedente Artículo precedente
  • A False Alarm
  • Manu Kaushik, Venkata M. Alla, Aryan Mooss
| Artículo siguiente Artículo siguiente
  • Psychiatric Comorbidity and Other Psychological Factors in Patients with “Chronic Lyme Disease”
  • Afton L. Hassett, Diane C. Radvanski, Steven Buyske, Shantal V. Savage, Leonard H. Sigal

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

@@150455@@ Voir plus

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2025 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.